Beneficial Ownership Report · SCHEDULE 13D/A
Medicus Pharma Ltd.
MDCXNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13D/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Medicus Pharma Ltd.
- Company CIK
- 0001997296
- Street
- 300 Conshohocken State Road
- Street (continued)
- Suite 200
- City
- West Conshohocken
- State / country code
- PA
- Postal code
- 19428
Statement details
- Amendment number
- 1
- Security class
- Common shares, no par value
- Event date
- 11/13/2026
- Previously filed indication
- false
Authorized notification person 1
- Name
- Dr. Raza Bokhari
- Phone
- 610-540-7515
- Street
- 300 Conshohocken State Road
- Street (continued)
- Suite 200
- City
- West Conshohocken
- State / country code
- PA
- Postal code
- 19428
Reporting person 1
- Name
- BOKHARI, RAZA
- Reporting person CIK
- 0001660525
- No reporting person CIK indication
- N
- Citizenship / organization
- X1
- Reporting person type
- IN
- Source of funds code
- PF · OO
- Legal proceedings indication
- N
- Aggregate amount owned
- 538,233.00
- Percent of class
- 19.1
- Sole voting power
- 86,424.00
- Shared voting power
- 451,909.00
- Sole dispositive power
- 86,424.00
- Shared dispositive power
- 451,909.00
- Aggregate excludes certain shares
- N
- Comments
- Includes (i) 27,500 common shares underlying stock options held by Dr. Raza Bokhari that are currently exercisable or will become exercisable within 60 days of the date hereof, (ii) 58,924 common shares held directly by Dr. Raza Bokhari and (iii) 451,909 common shares held by RBx Capital, LP, an entity controlled by Dr. Raza Bokhari (including the 436,046 common shares acquired by RBx Capital, LP in the Private Placement (as defined in Item 3)). Dr. Raza Bokhari may be deemed the beneficial owner of the securities held by RBx Capital, LP. Dr. Raza Bokhari disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Reporting person 2
- Name
- RBx Capital, LP
- No reporting person CIK indication
- Y
- Citizenship / organization
- DE
- Reporting person type
- PN
- Source of funds code
- WC
- Legal proceedings indication
- N
- Aggregate amount owned
- 451,909.00
- Percent of class
- 16.2
- Sole voting power
- 0.00
- Shared voting power
- 451,909.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 451,909.00
- Aggregate excludes certain shares
- N
Item 1
Issuer
Medicus Pharma Ltd.
Security title
Common shares, no par value
Principal address
Comment
This Amendment No. 1 to Schedule 13D (this "Amendment No. 1") amends and supplements the statement on Schedule 13D filed with the SEC on September 14, 2026 (the "Original Schedule 13D") by the Reporting Persons with respect to the common shares, no par value, of Medicus Pharma Ltd. (the "Issuer"). Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the Original Schedule 13D. Capitalized terms used but not defined herein have the meanings ascribed to them in the Original Schedule 13D.
Item 3
Source of funds
Item 3 of the Original Schedule 13D is hereby amended and supplemented as follows: On November 13, 2026, RBx Capital, LP, an entity controlled by Dr. Raza Bokhari, entered into a subscription agreement with the Issuer, pursuant to which RBx Capital, LP agreed to purchase 436,046 common shares (the "Private Placement Shares") in a private placement by the Issuer (the "Private Placement") at a purchase price of $1.72 per common share, for an aggregate purchase price of $749,999.12. The Private Placement Shares were acquired using the working capital of RBx Capital, LP.
Item 4
Purpose of transaction
Item 4 of the Original Schedule 13D is hereby amended and supplemented as follows: The information set forth in Item 3 of this Amendment No. 1 is incorporated herein by reference. RBx Capital, LP acquired the Private Placement Shares for general investment purposes. Except as set forth in this Item 4, the Reporting Persons do not currently have any plans or proposals that relate to or would result in any of the transactions or other matters specified in clauses (a) through (j) of Item 4 of Schedule 13D, although each Reporting Person reserves the right to formulate and pursue any such plans or proposals in the future, and to change its intentions with respect to any and all of the matters referred to in this Item 4.
Item 5
Number of shares
See Rows (7), (8), (9) and (10) of each Reporting Person's cover page.
Transactions
Except as described in Items 3 and 4 above of this Amendment No. 1, neither Reporting Person effected any transaction in the common shares during the 60 days preceding the date of the event that requires the filing of this statement.
Other persons with an interest
No person other than the Reporting Persons has the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, the common shares reported herein.
Date ownership ceased to exceed 5%
Not applicable.
Percentage of class
Item 5 of the Original Schedule 13D is hereby amended and restated in their entirety as follows: See Rows (11) and (13) of each Reporting Person's cover page. The percentages reported herein for RBx Capital, LP are calculated based on 2,788,106 common shares issued and outstanding as of November 16, 2026, as confirmed by the Issuer's transfer agent on such date. The percentages reported herein for Dr. Raza Bokhari are calculated based on 2,788,106 common shares issued and outstanding as of November 16, 2026, as confirmed by the Issuer's transfer agent on such date, plus 27,500 common shares underlying stock options held by Dr. Raza Bokhari that are currently exercisable or will become exercisable within 60 days of the date hereof.
Item 6
Contracts and arrangements
Item 6 of the Original Schedule 13D is hereby amended and supplemented as follows: The information set forth in Item 3 of this Amendment No. 1 is incorporated herein by reference.
Signature 1
- Reporting person
- BOKHARI, RAZA
- Signed
- /s/ Raza Bokhari
- Title
- Dr. Raza Bokhari
- Date
- 11/17/2026
Signature 2
- Reporting person
- RBx Capital, LP
- Signed
- /s/ Raza Bokhari
- Title
- Dr. Raza Bokhari, Managing Partner
- Date
- 11/17/2026
Company context
We are a clinical-stage, multi-strategy, life science and biotech company focused on investing in and accelerating the clinical development programs of novel and disruptive therapeutic assets. Currently, we are developing two products, SkinJectTM ("SkinJectTM"), with an indication for basal cell carcinoma, and Teverelix trifluoroacetate ("Teverelix", and together with SkinJectTM, the "Products").